Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Endeavor Biomedicines, Inc.
St. Jude Children's Research Hospital
Emory University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Fudan University
St. Jude Children's Research Hospital